SCHEMBL2067181

SCHEMBL2067181

COc1ncc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCC(O)C3)nc2C)c(=O)n4C)c(OC)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 14/20 0.47
ATM Q13315 11/20 0.43
PIK3CA P42336 10/20 0.43
ATR Q13535 9/20 0.43
PIK3CD O00329 3/20 0.40
PIK3CB P42338 3/20 0.40
PIK3CG P48736 3/20 0.40
P2RX3 P56373 1/20 0.39
CSNK2A2 P19784 1/20 0.39
FECH P22830 1/20 0.39
CLK1 P49759 1/20 0.39
GSK3A P49840 1/20 0.39
DYRK1A Q13627 1/20 0.39
MELK Q14680 1/20 0.39
MYLK3 Q32MK0 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
PIP4K2C Q8TBX8 1/20 0.39
TP53RK Q96S44 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067179 1.00 MTOR (0.47) MTORATMPIK3CAATRPIK3CD
SCHEMBL2067684 0.95 MTOR (0.46) MTORATMPIK3CAATRPIK3CD
SCHEMBL2068266 0.89 MTOR (0.43) MTORATMPIK3CAATRPIK3CD
SCHEMBL2068264 0.89 MTOR (0.43) MTORATMPIK3CAATRPIK3CD
SCHEMBL2068816 0.84 MTOR (0.48) MTORATMPIK3CAATRPIK3CD
SCHEMBL2068817 0.84 MTOR (0.48) MTORATMPIK3CAATRPIK3CD
SCHEMBL3515975 0.82 ATM (0.44) MTORATMPIK3CAATRPIK3CD
SCHEMBL3516026 0.82 ATM (0.44) MTORATMPIK3CAATRPIK3CD
SCHEMBL7876955 0.82 ATM (0.44) MTORATMPIK3CAATRPIK3CD
SCHEMBL7878799 0.82 ATM (0.44) MTORATMPIK3CAATRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP claimed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO claimed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US claimed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 MTOR 326/4885ATM 1084/4885PIK3CA 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.